Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Oruka Therapeutics has a Moderate Buy consensus from 11 brokerages, with 10 buy ratings and 1 sell rating. The average 12-month price target is $120.80.
• The stock opened at $64.59, near a 1-year range of $8.91 to $91.00, and the company has a market cap of $3.24 billion. Its latest quarterly earnings beat expectations, reporting -$0.45 EPS versus estimates for -$0.61.
• Insider selling has been notable, including shares sold by Joana Goncalves and CEO Lawrence Otto Klein, while institutional ownership remains high at 56.44%. The company is a clinical-stage biopharmaceutical firm, with lead candidate ONCT-01 in Phase 1 trials for advanced solid tumors.

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $120.80.

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, April 30th. Barclays upped their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a research note on Monday, April 27th. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research note on Monday, April 27th. Finally, Stifel Nicolaus upped their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a "buy" rating in a research note on Friday, March 13th.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $64.59 on Monday. The company's fifty day moving average price is $51.60 and its 200 day moving average price is $37.87. Oruka Therapeutics has a 1 year low of $8.91 and a 1 year high of $91.00. The company has a market capitalization of $3.24 billion, a PE ratio of -34.73 and a beta of -0.20.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.16. On average, equities analysts expect that Oruka Therapeutics will post -2.2 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $66.12, for a total value of $462,840.00. Following the completion of the sale, the insider owned 33,377 shares of the company's stock, valued at $2,206,887.24. This represents a 17.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the sale, the chief executive officer directly owned 927,309 shares of the company's stock, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 23,765 shares of company stock valued at $1,089,745. Corporate insiders own 23.49% of the company's stock.

Institutional Trading of Oruka Therapeutics

Several hedge funds have recently made changes to their positions in ORKA. Viking Global Investors LP purchased a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $51,280,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $51,840,000. Remedium Capital Partners LLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $47,054,000. Avoro Capital Advisors LLC purchased a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $25,640,000. Finally, Deep Track Capital LP boosted its position in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock worth $51,051,000 after purchasing an additional 735,983 shares during the period. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.